Pub. Date : 2017 Jan
PMID : 27942916
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | BACKGROUND: Despite decades of clinical success, tamoxifen therapy is complicated by inter-individual variability due to CYP450 polymorphism and resistance attributed to ERalpha/HER2 crosstalk. | Tamoxifen | erb-b2 receptor tyrosine kinase 2 | Homo sapiens |
2 | CONCLUSION: This forward-looking study extends the success of tamoxifen by exploring the effectiveness of combining the next-generation tamoxifen derivative, endoxifen with an anti-HER2 agent to combat ERalpha/HER2 crosstalk, and at the same time provides a solution to the predicted pharmacokinetic antagonism between lapatinib and tamoxifen. | Tamoxifen | erb-b2 receptor tyrosine kinase 2 | Homo sapiens |
3 | CONCLUSION: This forward-looking study extends the success of tamoxifen by exploring the effectiveness of combining the next-generation tamoxifen derivative, endoxifen with an anti-HER2 agent to combat ERalpha/HER2 crosstalk, and at the same time provides a solution to the predicted pharmacokinetic antagonism between lapatinib and tamoxifen. | Tamoxifen | erb-b2 receptor tyrosine kinase 2 | Homo sapiens |
4 | CONCLUSION: This forward-looking study extends the success of tamoxifen by exploring the effectiveness of combining the next-generation tamoxifen derivative, endoxifen with an anti-HER2 agent to combat ERalpha/HER2 crosstalk, and at the same time provides a solution to the predicted pharmacokinetic antagonism between lapatinib and tamoxifen. | Tamoxifen | erb-b2 receptor tyrosine kinase 2 | Homo sapiens |
5 | CONCLUSION: This forward-looking study extends the success of tamoxifen by exploring the effectiveness of combining the next-generation tamoxifen derivative, endoxifen with an anti-HER2 agent to combat ERalpha/HER2 crosstalk, and at the same time provides a solution to the predicted pharmacokinetic antagonism between lapatinib and tamoxifen. | Tamoxifen | erb-b2 receptor tyrosine kinase 2 | Homo sapiens |